They say that high school is supposed to be the best time of your life. But what if that’s just not true? More than anything, Mary Rose wants to fit in. She’ll do whatever it takes to make that happen, even if it costs her her life. Her compelling story will inspire readers—and remind them that they are not alone. Find our more at https://www.facebook.com/DEARNOBODY Dear Nobody The True Diary of Mary Rose YA and non-fiction
Mary Rose just wants to fit in and make friends…but that’s not that easy when you’re carrying around a deadly secret. Find out more at dearnobodydiary.com. YA, Non-Fiction
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
Just back from rehab, Mary Rose returns to her regular hang-out in pursuit of her “would-be” soul mate, Ryan. She is devastated when he shows up with another girl… and not just any girl either… a really pretty hippie girl, who is older, and maybe even cooler. The True Diary of Mary Rose. Find out more at http://dearnobodydiary.com non-fiction/ YA
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
The Ad Council, the largest producer of public service campaigns in the U.S., in partnership with Viacom, home to premier global brands in media and entertainment, and non-profit leader Facing Addiction today launched the PSA campaign “LISTEN” to ignite a national conversation about drug and alcohol addiction as a public health epidemic, and empower those impacted by substance use disorders.
While past PSA campaigns have traditionally focused on the perspective of those at risk, urging them to eliminate all substance use, “LISTEN” addresses the support system of people who are also affected by this crisis. Using powerful stories that portray the modern faces of addiction and recovery, the campaign looks to remove the stigma attached to substance misuse through the act of informed, compassionate listening. The campaign’s website, heretolisten.com, and Facing Addiction's Resource Hub provides important tools and information to help people start a productive conversation with their friends and loved ones and to support the more than 45 million Americans directly impacted by addiction.
To view the multimedia release go to:
http://www.multivu.com/players/English/8029751-ad-council-listen-psa-addiction-drug-alcohol-substance-abuse/
